From what I hear, this technology has potential to reduce, but not replace, biopsies. In a sense, clinicians will be able to obtain a more targeted biopsy of the gi tract, bronchus, etc at endoscopy by screening for dysplastic areas and not taking biopsies of obviously benign areas.
While there may be positive aspects to this, I think any and all anatomic pathologists should be somewhat concerned as to how this may shape future practice. Yes, difficult cases make our jobs interesting but the run of the mill TA vs. HP cases are the reason we can make a decent living. Take these away, and most of us are out of a job.
What I want to know are the opinions of others out there as to how much of an impact such new technology will make on our jobs as we know it, and when (5 yrs, 30 yrs, etc).
While this technology sounds good in theory, will clinicians embrace it anytime soon if there is extra training required, extra liability, decreased volume for their pod labs, and, as of now, no formal reimbursement?
While there may be positive aspects to this, I think any and all anatomic pathologists should be somewhat concerned as to how this may shape future practice. Yes, difficult cases make our jobs interesting but the run of the mill TA vs. HP cases are the reason we can make a decent living. Take these away, and most of us are out of a job.
What I want to know are the opinions of others out there as to how much of an impact such new technology will make on our jobs as we know it, and when (5 yrs, 30 yrs, etc).
While this technology sounds good in theory, will clinicians embrace it anytime soon if there is extra training required, extra liability, decreased volume for their pod labs, and, as of now, no formal reimbursement?